 |
| |
|
| |
_______________________________________
SPOTLIGHT: B-CELL
LYMPHOMAS
New funding accelerates research on B-cell
lymphomas |
| |
 Grants
and philanthropic donations -- the fiscal engine of cancer research --
fuel scientific
discoveries in the
lab and new therapies in the clinic that might otherwise remain
stalled. Recently, researchers in the DF/HCC Lymphoma and Myeloma
Program gained
greater traction on the battlefield against B-cell lymphomas from three
sources: the competitive renewal of an NCI program project grant, a new
Specialized Center of Research (SCOR) grant from the Leukemia and
Lymphoma Society, and a generous gift from a private donor. more
|
| |
_______________________________________
FOCI OF CANCER
RESEARCH
BIDMC: Exploiting biology to outwit cancer
|
| |
 "Our central vision in the Cancer Center is translating the research of basic
scientists into the solution of clinical problems," says Lowell Schnipper, MD,
chief of the Division of Hematology/Oncology at Beth Israel Deaconess Medical
Center, as well as deputy associate director for Clinical Sciences and member of
the Executive Committee at DF/HCC. To fulfill that vision, numerous research
programs are driving discovery from the bench to the bedside at this
100-year-old institution. Three areas of excellence, in particular, are
exploiting the biology of cancer -- to outwit it. more |
| |
______________________________________
MORE ON
CORES
Analyzing the pathology of tumors
|
| |
"Detailed analysis of tumor tissue plays an essential
role in cancer research, from discovery of disease mechanisms to evaluation of
new therapies," says Jon Aster, director of the Specialized
Histopathology Services Core. Two sites (Longwood and MGH) perform a spectrum of tissue-based
services including processing, histological
staining, and immunohistochemistry. Longwood also offers in situ hybridization, automated blood-cell counting for rodent and
non-human primate samples, and access to a laser-capture microdissection
system; both sites offer expert pathology consultation and interpretation
assistance. For information about the Longwood Core, contact Donna
Skinner, for the
MGH Core, contact Candice Romany.
To create a new account, visit our website and follow these instructions (PDF).
|
| |
Searching the proteome for answers |
| |
When
translational researchers recently sought to identify biomarkers for
hepatocellular cancer and myelodysplastic syndrome, they knew exactly where to
turn. The Cancer Proteomics
Core uses the most
advanced functional proteomics tools to profile, fractionate, identify, and
quantify proteins and to discover and validate biomarkers from a variety of
samples (serum, plasma, urine, CSF, tumor tissue, cell lysates). The Core's
comprehensive services also include customized consultation and education. For
more information, visit our website or
contact Core
director Towia
Libermann
or John Asara.
|
| |
Applying the art of communication to your
science |
| |
 Do you need a recruitment poster or an educational booklet? An interactive website or a CD-ROM? The
Health Communication
Core
can help.
The
Core's creative team -- with expertise in writing, graphic design,
website development, translation coordination, and a host of other
unique
communication services -- will help you connect more effectively with
the audiences that benefit from your research. For information on how
your
studies can become more successful through the art of communication,
e-mail Core manager Brad
Kaiser.
|
| |
______________________________________
NODES AND
SYNERGIES
DF/HCC members now lead 7 SPOREs, 32 PO1 grants |
| |
Specialized Programs of Research Excellence (SPOREs) promote
interdisciplinary collaboration that moves basic research findings from
the laboratory
to
clinical settings, while program project grants support
multidisciplinary, long-term efforts directed toward a range of
problems with a central
research focus. For more information, see SPOREs and PO1s.
|
| |
Cores' services help advance cancer
research
Core Facilities -- central laboratories that each perform a specific
set of services -- serve DF/HCC members across all seven institutions
to
increase interactivity among investigators, execute project-related
experiments, and provide expert advice and consultation. Because Cores
play a key
role in facilitating multi-investigator, inter-institutional
collaboration, they are essential elements of disease programs as well
as SPORE and PO1
grant activities. For more information, see List of Cores and List of Core Directors.
|
| |
|
| |
DF/HCC launches Disparities website for researchers
|
| |
The
DF/HCC Initiative to Eliminate Health Disparities (IECD) has many
programs but one primary goal -- to eliminate racial, ethnic, and
socioeconomic
inequities in cancer care and prevention. The IECD recently launched a
website to disseminate information and support researchers' efforts to
end
cancer disparities. We invite you to explore the website to learn
more
about IECD events - and how to get involved.
|
| |
______________________________________
SAVE THE
DATE
|
| |
DF/HCC External Advisory Board Meeting
October 17-18, 2006
8:00 a.m. to 5:00 p.m. (10/17) and
8:00 a.m. to 1:00 p.m. (10/18)
Smith 308, DFCI
DF/HCC "Pipelines in Oncology"
Note: These presentations are designated for DF/HCC members only.
October 19
Pfizer
4:00 to 6:00 p.m.
Dana 1620, DFCI (videoconference to Haber Room, MGH)
December 19
Novartis
4:00 to 6:00 p.m.
Dana 1620, DFCI (videoconference to Haber Room, MGH)
|
| |
|
| |
|
|
|
_________________
NEWS AND
EVENTS
Four DF/HCC scientists elected to
the Institute of Medicine
The National Academy of Sciences announced October 9 that Nancy
Andrews, MD, PhD (CHB), Graham
Colditz, MD, DrPH (BWH/HSPH), Stephen Elledge, PhD (BWH), and Robert
Martuza, MD
(MGH), were among 65 new members elected to the Institute of Medicine.
Upon election, one of the most prestigious honors in
medicine and health, members commit to serving on IOM study committees,
which advise policymakers, health professionals, the private sector,
and the
public. more
Segal wins Pioneer Award for
studies of mitogenic
niche
In September, Rosalind Segal, MD, PhD (DFCI), professor of
neurobiology, received the 2006 NIH
Director's Pioneer Award, a
five-year, $2.5 million grant given to an outstanding scientist who
pioneers new approaches to biomedical research. Segal's research has
shown, in studies of the developing brain, that a well-characterized
mitogenic niche (the microenvironment of stem cells) requires
carbo-
hydrates to develop and grow normal cells - as well as tumor
cells. more |
|
Interdisciplinary symposium
targets PI3K pathway
On October 4, the Center Scientific Council (CSC) hosted
a symposium titled "Targeting the PI3K Pathway for Cancer Therapy," the
first
of a quarterly series of workshops on emerging avenues of
interdisciplinary research. Chaired by Lewis Cantley, PhD (BIDMC), the
event featured
presentations on PI3K/PTEN in breast cancer, identifying PI3K-activated
tumors, mouse models for PI3K-driven tumors, and clinical trials of
PI3K
inhibitors. more
Program matches mentors to
minority students
Capping a rigorous nine weeks of research, 21 students recently
presented their findings to an audience of scientists
and lab mates,
family and friends. Under the Continuing Umbrella of Research
Experiences (CURE) program, sponsored by the NCI, promising high school
and college
students from under-
represented populations can sample the intellectual
excitement of biomedical research firsthand. more
|
_________________
RESEARCH HIGHLIGHTS
For details, click on links.
Beth
Israel Deaconess Medical Center -- Rapamycin
shown to inhibit
angiogenesis
Brigham and Women's Hospital -- New tool helps determine risk of colon cancer
Children's Hospital
Boston -- Genetic profile predicts
outcomes in some
cancers
Dana-Farber Cancer
Institute -- Study suggests novel way of
preventing skin cancer
Harvard Medical School
-- Hunt for DNA amplified in cancers uncovers target gene
Harvard School of Public Health -- Analyses confirm breast density estimates breast cancer
risk
Massachusetts General
Hospital -- Prostate
cancer drug raises heart, diabetes risk
_________________
New Faces
Eleven new members join DF/HCC community
Since June, 11 individuals from our seven member institutions and
academic partners have joined DF/HCC -- adding new expertise to the
collaborative effort
to conquer cancer. To learn more about these scientists and their areas
of research interest, click here.
|
|
